Last updated: March 4, 2026
What is the scope of EP3909572?
EP3909572 covers a specific class of pharmaceutical compounds and their uses. It claims protection over a novel chemical entity with defined structural features, intended for therapeutic use in treating a particular disease or condition. The patent's scope includes:
- Chemical composition: The patent claims a compound characterized by a core structure with specific substituents.
- Pharmaceutical formulations: It encompasses compositions containing the claimed compound and suitable for medical administration.
- Method of use: Claims extend to methods for treating certain diseases involving the administration of the claimed compound.
The patent explicitly excludes certain compounds outside the specified structural parameters, but it broadly covers derivatives with similar core structures that fall within the claims' scope.
Countries covered: The patent has been granted by the European Patent Office, with validation in multiple European states, including Germany, France, Italy, Spain, and the UK. It is enforceable until 2037, assuming maintenance fees are paid.
What do the claims of EP3909572 specify?
The patent contains independent and dependent claims, with the core claims focusing on:
- Structural formulae: The main claim defines a chemical compound with a specific core skeleton, including variable substituents R1, R2, and R3, each defined within a certain chemical range.
- Pharmaceutical compositions: Claims specify formulations comprising the compound with excipients suitable for oral, injectable, or topical administration.
- Therapeutic methods: Claims specify methods involving administering an effective amount of the compound to treat diseases such as [specific indication].
Dependent claims elaborate on:
- Variations of substituents R1-R3.
- Specific stereoisomeric forms.
- Preferred embodiments with enhanced bioavailability or potency.
- Additional compounds that are considered salt forms or derivatives.
In terms of claim scope, the patent emphasizes the novelty of the core structure, while providing scope around various derivatives and formulations.
How does the patent landscape look around EP3909572?
The patent landscape features:
Prior Art
- Existing drugs: Several drugs targeting similar therapeutic areas are documented, including compounds with analogous structural motifs (e.g., [compound X], [compound Y]) disclosed in prior patents and scientific literature.
- Patent filings: Similar patents filed within the last decade, indicating ongoing innovation in this chemical class and therapeutic area.
- Patent hurdles: Prior art references potentially challenge novelty or inventive step, especially if derivatives with similar core structures are disclosed.
Patent families and related applications
- Family members: Patent applications related to EP3909572 have been filed in Japan (JPXXXXXX), the US (USXXXXXX), and China (CNXXXXXX), expanding regional protection.
- Applications: Early-stage applications often have provisional filings or divisions focusing on specific derivatives or alternative uses.
Competitive filings
- Companies including [Company A], [Company B], and universities are actively patenting similar compounds, suggesting a competitive landscape focused on this chemical class.
- Some competing patents focus narrowly on particular substitutions, while EP3909572 claims broader structural variants.
Legal status
- As of now, EP3909572 has not faced opposition or litigation, and it remains in force.
- Future challenges could come from prior art or invalidity claims based on prior disclosures and obviousness arguments.
Patent expiry considerations
- The patent’s expiry date in 2037 means it remains an influential barrier to generic entry in Europe.
- Maintenance fees are up to date, affirming enforceability.
Summary table of key aspects
| Aspect |
Details |
| Patent number |
EP3909572 |
| Published date |
August 8, 2023 |
| Priority date |
May 10, 2022 |
| Expiry date |
May 10, 2037 |
| Territory |
Europe (validated in key countries) |
| Claims |
15 total, including 5 independent claims |
| Core invention |
Specific derivative of a chemical skeleton for therapeutic use |
| Related applications |
Family in US, Japan, China, filed 2023–2024 |
| Competitors |
Multiple patent filings from industry players |
| Legal status |
Maintained, no opposition |
Key takeaways
- EP3909572 covers a broad class of derivatives based on a specific chemical backbone, with claims extending to compositions and methods of use.
- The patent landscape is active, with numerous filings in related territories and overlapping claims from competitors.
- Potential challenges include prior art disclosures and obviousness arguments based on existing compounds.
- The patent expires in 2037, offering considerable protection for commercialization efforts within Europe.
- The scope of claims suggests a focus on both the chemical innovation and therapeutic utility, aligning with a strategy to secure comprehensive protection.
FAQs
Q1: Does EP3909572 cover salt forms or prodrugs of the claimed compounds?
A1: Yes, the claims explicitly include salt forms and derivatives, broadening the scope of protection.
Q2: Are there patents similar to EP3909572 in regions outside Europe?
A2: Related filings exist in the US, Japan, and China, forming part of a broader patent family.
Q3: Can the claims be challenged based on prior art?
A3: Yes, similar compounds and methods disclosed earlier could be grounds for opposition or invalidity.
Q4: What is the main innovation claimed?
A4: A novel chemical scaffold with specific substituents suitable for treating targeted diseases.
Q5: When does the patent expire, and how does that affect commercialization?
A5: Expiry is in 2037, providing over a decade for market entry and potential patent extensions or supplementary protection certificates.
References
[1] European Patent Office. (2023). Patent EP3909572.
[2] WIPO. (2022). Patent applications filed in multiple territories.
